Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Coeptis Therapeutics Holdings had a gross margin of 94.78% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Coeptis Therapeutics Holdings Gross Margin % Related Terms
Coeptis Therapeutics Holdings Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COEP vs ANIX, COYA, PMN: Gross Margin % Comparison
For the Biotechnology subindustry, Coeptis Therapeutics Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coeptis Therapeutics Holdings Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coeptis Therapeutics Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Coeptis Therapeutics Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Coeptis Therapeutics Holdings (COEP) has a Gross Margin % of 94.78% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Coeptis Therapeutics Holdings and its competitors. According to the industry distribution chart, Coeptis Therapeutics Holdings ranks #152 out of 736 companies in the Biotechnology industry, placing it in the top 20.7%.
Is Coeptis Therapeutics Holdings' Gross Margin % too high?
Coeptis Therapeutics Holdings' current Gross Margin % is 94.78%. The Biotechnology industry median Gross Margin % is 60.91. Coeptis Therapeutics Holdings' value of 94.78% is 55.6% above this industry median. Based on the distribution chart, Coeptis Therapeutics Holdings ranks #152 out of 736 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Coeptis Therapeutics Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Coeptis Therapeutics Holdings' Gross Margin % compare to ANIX and COYA?
According to the Biotechnology industry distribution chart, Coeptis Therapeutics Holdings ranks #152 out of 736 companies for Gross Margin %. This places Coeptis Therapeutics Holdings in the top 21% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Coeptis Therapeutics Holdings' value of 94.78% is 55.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coeptis Therapeutics Holdings's current Gross Margin % of 94.78% is 55.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Coeptis Therapeutics Holdings and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coeptis Therapeutics Holdings's current Gross Margin % is 94.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coeptis Therapeutics Holdings stock overvalued right now?
Coeptis Therapeutics Holdings (COEP) has a current Gross Margin % of 94.78%. The current Gross Margin % is 94.78% and 55.6% above the Biotechnology industry median of 60.91. Coeptis Therapeutics Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Coeptis Therapeutics Holdings (COEP), the current Gross Margin % is 94.78% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Coeptis Therapeutics Holdings Business Description
Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.
12GF Score
Get the complete analysis for COEP
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COEP has been successfully added to your 
